Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CLL-1 CAR-NK Cells in Relapsed/Refractory AML
NCT06307054Phase 1Recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Apr 2024
- Primary completion
- Mar 2026
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CLL1 CAR-NK cells in acute myeloid leukemia (AML), sponsored by Shanghai General Hospital. Primary endpoints: Adverse Events at 28 days and Dose-Limiting Toxicity at 28 days. Started Apr 2024; status: recruiting.
02
Drugs
CLL1 CAR-NK cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06307054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06307054.